Sunesis Pharmaceuticals, Inc. (SNSS)
-NasdaqCM 5.23 
0.08(1.51%) 4:00PM EDT|After Hours
:
5.23 0.00 (0.00%) 4:27PM EDT
| Prev Close: | 5.31 |
|---|
| Open: | 5.37 |
|---|
| Bid: | 4.77 x 200 |
|---|
| Ask: | 5.75 x 3500 |
|---|
| 1y Target Est: | 8.82 |
|---|
| Beta: | 2.66 |
|---|
| Next Earnings Date: | 13-May-13 |
|---|
| Day's Range: | 5.20 - 5.43 |
|---|
| 52wk Range: | 2.30 - 6.85 |
|---|
| Volume: | 156,048 |
|---|
| Avg Vol (3m): | 415,990 |
|---|
| Market Cap: | 269.78M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.91 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Sunesis to Host Conference Call on May 9th to Discuss First Quarter Financial Results and Recent HighlightsGlobeNewswire(Thu 7:00AM EDT)
- Incremental Changes in Regulatory Environment Beneficial to Development-Stage Biotech Companies Due to Emphasis on Closer Working Relationships with the FDA and Drug SponsorsWall Street Transcript(Wed, May 1)
- Sunesis to Present at the Needham & Company 12th Annual Healthcare ConferenceGlobeNewswire(Wed, Apr 24)
- SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements andEDGAR Online(Wed, Apr 10)
- Over $400 Million Raised by U.S. Life Sciences Companies Through At-the-Market (ATM) Offerings in 2012, Reports Brinson PatrickPR Newswire(Mon, Apr 8)
- SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and EEDGAR Online(Wed, Mar 27)
- Hedge Funds Are Buying 3 Undervalued Stocks With Short Coveringat Seeking Alpha(Tue, Mar 26)
- SARcode's clear vision on dry eye drug nets Shire dealat bizjournals.com(Tue, Mar 26)
- Vosaroxin: A Promising Drug For A Difficult Diseaseat Seeking Alpha(Thu, Mar 21)
- SUNESIS PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Tue, Mar 19)
- New Star Analyst Rankings for Sunesis Pharmaceuticals, Inc.StarMine(Thu, Mar 14)
- U.S. Food and Drug Administration Approved 30% More Drugs in 2012 Than the Year PreviousMarketwired(Thu, Mar 14)
- Sunesis Pharma Loss Narrows in Q4, Widens in 2012at Motley Fool(Wed, Mar 13)
- Netflix, Dole, Express are big moversAP(Wed, Mar 13)
- Sunesis Pharmaceuticals Management Discusses Q4 2012 Results - Earnings Call Transcriptat Seeking Alpha(Wed, Mar 13)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 72.96 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.76 |
|---|
| Quarterly EPS Est
(Mar-13)
: | -0.20 |
|---|
| Mean Recommendation*: | 1.6 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers.
View More